Viatrexx-Lymph 1 Recalled Due to Lack of Sterility Assurance
Viatrexx Bio Incorporated is recalling Viatrexx-Lymph 1 vials because the manufacturing process cannot guarantee sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric, particularly given the risk of infection from non-sterile medical products.
Plain-English summary
Viatrexx Bio Incorporated is recalling Viatrexx-Lymph 1, 10 mL sterile multi-dose vials (NDC 73069-310-41). The recall is due to a lack of assurance of sterility, as the products were manufactured in a manner that cannot guarantee their sterility.
The affected product is identified by Lot Number 19-S00017 with an expiration date of May 2020. The product was distributed to physicians nationwide throughout the United States and Puerto Rico.
Consumers and healthcare providers should stop using the affected product and contact the manufacturer or their supplier for further instructions.
The recalled product
- Product
- Viatrexx-Lymph 1, 10 mL Sterile multi-dose vial, Rx only, Viatrexx Bio Incorporated, Newark, DE, USA, 19713, Item: VSPC0370, NDC 73069-310-41.
- Manufacturer
- 8046255 Canada Inc. DBA Viatrexx
- Category
- Drug — Biologic
- Affected units
- 3
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Numbers: 19-S00017
- Exp. May: 2020
Distribution
Part of a larger recall action
This product is one of 23 recalled by 8046255 Canada Inc. DBA Viatrexx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 23 products in this recall →Related recalls
Same manufacturer · 8046255 Canada Inc. DBA Viatrexx
See all →- SevereViatrexx-Mesenchyme Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2019-11-20
- SevereViatrexx-MuSkel-Neural Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2019-11-20
- SevereViatrexx-Systemic Detox Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2019-11-20
- SevereViatrexx-Neuro Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2019-11-20
- SevereViatrexx-GI Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2019-11-20
Same hazard · infection
See all →- SevereSafeguard US Operating LLC Recalls Compression Bandages Due to Degradation
FDA (Devices) · 2026-10-14
- SevereStryker Bard EP XT Decapolar Steerable Diagnostic EP Catheter Recalled for Sterile Barrier Breach
FDA (Devices) · 2026-10-14
- HighEmbosphere Microspheres Recalled Due to Packaging Sterility Concerns
FDA (Devices) · 2026-10-07
- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- HighFDA Recalls Performance Pro Nitrile Gloves Due to Defects
FDA (Devices) · 2026-10-07
Similar recalls
- HighAlkermes Recalls VIVITROL Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-07-31
- HighCompounded Semaglutide Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-09-11
- HighTirzepatide Injectable Drug Recalled for Sterility Assurance Defect
FDA (Drugs) · 2024-09-11
- SevereAssurance Infusion Recalls QUADMIX Vials Due to Sterility Concerns
FDA (Drugs) · 2020-01-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereVital Rx Recalls Sterile Products Due to Sterility Assurance Concerns
FDA (Drugs) · 2017-12-27